Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

EPI Health and MC2 Therapeutics announces U.S. Launch of Wynzora® Cream for Plaque Psoriasis (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)


News provided by

EPI Health , MC2 Therapeutics

19 Jul, 2021, 12:00 GMT

Share this article

Share toX

Share this article

Share toX

This image opens in the lightbox
EPI logo (PRNewsfoto/EPI Health)
This image opens in the lightbox
MC2_logo (PRNewsfoto/MC2 Therapeutics)

 Now available: Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) once-daily topical treatment of plaque psoriasis in adults 18 years of age or older introduces use of PAD™ Technology. 

·  Wynzora is the first and only water-based cream that uses PAD™ technology to help optimize the treatment of plaque psoriasis (ref. USPI)

·  For 95% of adult psoriasis patients in the US a topical therapy is the first-line therapy used1

·  When measured on a 50-point treatment convenience scale, patients rated Wynzora at 84% on ease of application, non-greasy application, and minimal disruption of daily routine among other measures

Wynzora® Cream will be available for commercial supply starting July 19, 2021, in the United States.

CHARLESTON, S.C. and COPENHAGEN, Denmark, July 19, 2021 /PRNewswire/ -- EPI Health and MC2 Therapeutics, announced today commercial availability in the United States of Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for the topical treatment of plaque psoriasis in adults, 18 years of age or older.

"Calcipotriene and betamethasone dipropionate are well-established molecules for the treatment of plaque psoriasis, with proven efficacy, safety and tolerability. Until now they could not be combined into an aqueous cream, which is less greasy and more user-friendly than other formulations." – John Koo MD, Professor of Dermatology at University of California San Francisco medical center and Co- Director, UCSF Psoriasis Treatment Center, Phototherapy unit and Psychodermatology clinic. Board certified in Dermatology and Psychiatry.

"As a leader in Dermatology, expanding our portfolio to help address some of the issues faced by almost 8 million people 2 in the US with psoriasis aligns with our mission to provide safe, beneficial, and effective medications, such as Wynzora®, to the dermatology community." said John Donofrio, President of EPI Health.

"The development and unique design of Wynzora® was aimed at providing efficacy, safety, and convenience in a single topical product." commented Jesper J. Lange, CEO of MC2 Therapeutics, and continues, "Our collaboration with EPI Health in the preparation of the launch has been excellent and we are excited that Wynzora® is now available for patients."

About Plaque Psoriasis

Psoriasis is a common, non-contagious, chronic skin disease, with no clear cause or cure. The negative impact of plaque psoriasis on people's lives can be immense as it affects the appearance of the skin with red, scaly plaques. The appearance of flares of psoriasis can be unpredictable and affects people of all ages. With a reported prevalence of 2-4% of the population psoriasis constitutes a serious health problem with more than 100 million individuals affected worldwide. More than 90% of patients receiving treatment use topical drugs. According to the National Psoriasis Foundation, itch is present in between 70 and 90 percent of psoriasis patients, and together with flaking and scaling, itching is the most burdensome symptom to patients.3,4 Patients with psoriatic disease are at an elevated risk of developing other chronic and serious health conditions, including arthritis, cardiovascular diseases, metabolic syndrome, inflammatory bowel disease and depression.3

About Wynzora® Cream

Wynzora Cream is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis. Wynzora® Cream is based on PAD™ Technology, which uniquely enables stability of both calcipotriene and betamethasone dipropionate in a convenient-to-use aqueous formulation. Wynzora® Cream was uniquely designed to provide patients a new treatment option in their daily routines by combining the three essentials of a topical therapy in one single product: high efficacy, a favorable safety profile and convenience of use. In the phase 3 trials conducted at multiple sites in the US and the EU, Wynzora® Cream has demonstrated a unique combination of compelling clinical efficacy, a favorable safety profile and high convenience.

For more information, please visit www.wynzora.com.

Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) Indication and ISI4

Indication and Usage

Wynzora® (calcipotriene and betamethasone dipropionate) Cream is indicated for plaque psoriasis in adults. It is not known if Wynzora Cream is safe and effective in children.

Important Safety Information

  • Wynzora Cream is for topical use only.
  • Patients should not use more than 100g of Wynzora Cream per week.
  • Wynzora Cream should not be used near or in the mouth, eyes, or intravaginally.
  • Patients should avoid using Wynzora Cream on the face, groin, or armpits, or if they have atrophy at the treatment site.
  • Patients should apply Wynzora Cream to the affected areas of the skin once a day for up to 8 weeks.
  • Patients should discontinue use once the plaque psoriasis is under control.
  • Patients should not use with occlusive dressings.
  • Hypercalcemia and hypercalciuria have been observed with use of topical calcipotriene.
  • Wynzora Cream can cause reversible HPA axis suppression with the potential for clinical glucocorticosteroid insufficiency during and after withdrawal of treatment.
  • Wynzora Cream may cause vision problems, including increasing the risk of cataracts and glaucoma.
  • It is not known whether Wynzora Cream may harm your unborn baby.
  • Breastfeeding women should not apply Wynzora Cream directly to the nipple and areola.
  • It is not known whether topically administered calcipotriene and betamethasone dipropionate is absorbed in human milk.

Please see accompanying full Prescribing Information for Wynzora cream.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call1-800-FDA-1088.

About EPI Health

Headquartered in Charleston, South Carolina, EPI Health is a specialty pharmaceutical company established as a leader and one of the fastest growing companies in the US dermatology community. EPI is committed to delivering innovative prescription therapies to dermatologists while improving the quality of life for patients and providing outstanding medical services. Its current portfolio includes medicines to patients with rosacea, atopic dermatitis, cold sores, and acne. EPI Health is a wholly owned subsidiary of Evening Post Industries.

For additional information please visit www.epihealth.com

About MC2 Therapeutics

MC2 Therapeutics is a privately held commercial stage pharmaceutical company developing a new standard of topical therapies for chronic inflammatory conditions. Using its PAD™ Technology it aims to set a new standard of treatment experience for patients and to release the full potential of novel topical drugs for the benefit of patients, physicians, payers and societies. PAD™ Technology is the cornerstone for the innovative pipeline of drug candidates within atopic dermatitis, dry eye, ocular rosacea, uremic pruritus and lichen sclerosis.

For additional information please visit www.mc2therapeutics.com

About PAD™ Technology

PAD™ Technology formulations are tailor-made to meet the target product profile for a selected product candidate. PAD™ Technology enables the mixing of oil and water into a cream using just a fraction of the emulsifier required in conventional creams and lotions. Key features of PAD™ Technology formulations are high penetration of active ingredients to the target tissue, improved solubility and stability of active ingredients, high tolerability and excellent treatment convenience.

1 Murage MJ, Kern DM, Chang L, Sonawane K, Malatestinic WN, Quimbo RA, Feldman SR, Muram TM, Araujo AB. Treatment patterns among patients with psoriasis using a large national payer database in the United States: a retrospective study. J Med Econ. 2018 Oct 25:1-9.

2 https://www.psoriasis.org/psoriasis-statistics/

3 WHO Global report on Psoriasis 2016, p.13 - 16

4 Prescribing Information for Wynzora. July 2020.

Logo - https://mma.prnewswire.com/media/1571833/EPI_Health_Logo.jpg
Logo - https://mma.prnewswire.com/media/1571834/MC2_Therapeutics_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.